Director/PDMR Shareholding

RNS Number : 3595J
GlaxoSmithKline PLC
26 April 2022
 

GlaxoSmithKline plc   (the ' Company ')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$44.8700

1,147.942

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-04-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHVQLBLLZLLBBV

Companies

GSK (GSK)
UK 100

Latest directors dealings